<DOC>
	<DOCNO>NCT00150891</DOCNO>
	<brief_summary>Chronic transplant rejection remain main cause late kidney graft loss . We show previously patient pretransplant CD4 helper defect low in-vitro IL-10 response demonstrate extremely low risk acute rejection significantly well 1- 3-year graft function whereas pretransplant Th1 response predictive ( Weimer R et al . 1996 1998 ) . In liver transplant recipient , find CD4 helper function in-vitro IL-10 response significantly decrease compare CsA-treated patient ( Zipperle et al . 1997 ) . If effect demonstrate renal transplant recipient , Tacrolimus ( Tacr ) treatment might result enhanced graft survival compare CsA , CD4 helper function in-vitro IL-10 response individual patient elevate . Other study group suggest beneficial role enhance T-suppressor activity IL-6 independent B cell/monocyte defect maintenance long-term stable graft function , whereas enhanced monokine secretion ( TNF-a , GM-CSF , IL-6 ) find chronic rejection ( Weimer et al . 1990 , 1992 , 1994 , 1998 ) . In current randomized prospective study analyze impact CsA versus Tacr MMF versus azathioprine Th1 , Th2 monokine response predictive value regard occurrence acute chronic rejection . With proposed follow-up 5 year study might enable patient-tailored immunosuppressive therapy result prolonged graft survival .</brief_summary>
	<brief_title>Th1 , Th2 Monokine Responses Risk Factors Renal Transplant Rejection</brief_title>
	<detailed_description>Chronic transplant rejection remain main cause late kidney graft loss . We show previously patient pretransplant CD4 helper defect low in-vitro IL-10 response demonstrate extremely low risk acute rejection significantly well 1- 3-year graft function whereas pretransplant Th1 response predictive ( Weimer R et al . 1996 1998 ) . In liver transplant recipient , find CD4 helper function in-vitro IL-10 response significantly decrease compare CsA-treated patient ( Zipperle et al . 1997 ) . If effect demonstrate renal transplant recipient , Tacrolimus ( Tacr ) treatment might result enhanced graft survival compare CsA , CD4 helper function in-vitro IL-10 response individual patient elevate . Other study group suggest beneficial role enhance T-suppressor activity IL-6 independent B cell/monocyte defect maintenance long-term stable graft function , whereas enhanced monokine secretion ( TNF-a , GM-CSF , IL-6 ) find chronic rejection ( Weimer et al . 1990 , 1992 , 1994 , 1998 ) . In current randomized prospective study analyze impact CsA versus Tacr MMF versus azathioprine ( Aza ; 3 treatment group : CsA/Aza , CsA/MMF Tacr/Aza ; steroid prophylactic ATG treatment accord Giessen protocol ) immune parameter predictive value regard occurrence acute chronic rejection . As immune parameter assess CD4 helper function , in-vitro IL-4 IL-10 response T cell CD4+ T cell , respectively , allogeneic cocultures patient T cell control B cell PHA-stimulated T cell culture , T-cell dependent ( PWM-stimulated allogeneic cocultures ) T-independent ( SAC I-stimulated B cell culture ) immunoglobulin-secreting cell ( ISC ) responses , B-cell IL-6 IL-10 response monokine response ( LPS-stimulated monocyte culture ) pretransplant , 4 month , 1 year , 2 year 5 year posttransplant . Serum cytokine easily measurable parameter neopterin , sIL-1RA sCD30 assess time point . The true flow cytometric analysis cytokine receptor , adhesion molecule , costimulator molecule surface molecule expression , respectively , play important role cell-cell interaction tolerance induction . Cytokine promoter gene polymorphism determine potentially enable pretransplant risk estimation . To establish broadly available rapid diagnostic method , compare data intracellular cytokine test result much difficult time consume coculture analysis use previous study . With proposed follow-up 5 year prospective randomize study might enable patient-tailored immunosuppressive therapy result good graft function prolong graft survival prevent chronic allograft rejection . Weimer R , Pomer S , Staehler G , Opelz G. Increased T suppressor activity renal transplant recipient long-term stable graft function . Clinical Transplantation 1990 ; 4 : 280-286 Weimer R , Zipperle S , Daniel V , Pomer S , Staehler G , Opelz G. In vitro B cell response long-term renal transplant recipient . Transplant Proc 1992 ; 24 ( 6 ) : 2537-2538 Weimer R , Zipperle S , Daniel V , Pomer S , Staehler G , Opelz G. IL-6 independent monocyte/B cell defect renal transplant recipient long-term stable graft function . Transplantation 1994 ; 57 ( 1 ) : 54-59 Weimer R , Zipperle S , Daniel V , Carl S , Staehler G , Opelz G. Pretransplant CD4 helper function IL-10 response predict risk acute kidney graft rejection . Transplantation 1996 ; 62 ( 11 ) : 1606-1614 Zipperle S , Weimer R , Golling M , Daniel V , Otto G , Opelz G. Impaired T cell IL-10 secretion CD4 helper function liver transplant patient treat tacrolimus . Transplant Proc 1997 ; 29 ( 1-2 ) : 1079-1080 Weimer R , Zipperle S , Daniel V , Carl S , Staehler G , Opelz G. Superior 3-year kidney graft function patient impaired pretransplant Th2 response . Transplant Int 1998 ; 11 ( Suppl 1 ) : 350-356</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Azathioprine</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Renal transplant recipient Giessen renal transplant unit Contraindications bloodtaking ( anemia hemoglobin &lt; 9.5 g/l , hypotension etc . ) No informed consent patient</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>Th1</keyword>
	<keyword>Th2</keyword>
	<keyword>B cell</keyword>
	<keyword>monokines</keyword>
	<keyword>kidney transplantation</keyword>
	<keyword>acute rejection</keyword>
	<keyword>chronic rejection</keyword>
</DOC>